Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI

References

• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Morris VK , KennedyEB, BaxterNNet al. Treatment of metastatic colorectal cancer: ASCO guideline. J. Clin. Oncol.41(3), 678–700 (2023).
   PubMed Web of Science ®Google Scholar
• Benson AB , VenookAP, Al-HawaryMMet al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw.19(3), 329–359 (2021).
   PubMed Web of Science ®Google Scholar
• Raica M , CimpeanAM, RibattiD. Angiogenesis in pre-malignant conditions. Eur. J. Cancer45(11), 1924–1934 (2009).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA. Hallmarks of cancer: The next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , TaberneroJ, LakomyRet al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol.30(28), 3499–3506 (2012).
   PubMed Web of Science ®Google Scholar
• Loupakis F , AntonuzzoL, BachetJBet al. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther. Adv. Med. Oncol.12, 1758835920956862 (2020).
   Web of Science ®Google Scholar
• Hurwitz H , FehrenbacherL, NovotnyWet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Tabernero J , YoshinoT, CohnALet al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol.16(5), 499–508 (2015).
   PubMed Web of Science ®Google Scholar
• Cremolini C , LoupakisF, AntoniottiCet al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.16(13), 1306–1315 (2015).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , TaberneroJ, LakomyRet al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol.30(28), 3499–3506 (2012).
   PubMed Web of Science ®Google Scholar
• Erol C , SendurMAN, BilgetekinIet al. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: real-life data from Turkish oncology group. J. Cancer Res. Ther.18(12 Suppl. 2), 347–353 (2022).
   Google Scholar
• Fernández Montes A , MartínezLago N, CovelaRúa Met al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med.8(3), 882–889 (2019).
   PubMed Web of Science ®Google Scholar
• Ivanova JI , SavernoKR, SungJet al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med. Oncol.34(12), 193 (2017).
   PubMed Web of Science ®Google Scholar
• Palmer BF , GatesJR, LaderM. Causes and management of hyponatremia. Ann. Pharmacother.37(11), 1694–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Berghmans T , PaesmansM, BodyJJ. A prospective study on hyponatraemia in medical cancer patients: Epidemiology, aetiology and differential diagnosis. Support Care Cancer8(3), 192–197 (2000).
   PubMed Web of Science ®Google Scholar
• Hansen O , SørensenP, HansenKH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer68(1), 111–114 (2010).
   PubMed Web of Science ®Google Scholar
• Castillo JJ , VincentM, JusticeE. Diagnosis and management of hyponatremia in cancer patients. Oncologist17(6), 756–765 (2012).
   PubMed Web of Science ®Google Scholar
• Abu Zeinah GF , Al-KindiSG, HassanAA, AllamA. Hyponatraemia in cancer: association with type of cancer and mortality. Eur. J. Cancer Care (Engl.)24(2), 224–231 (2015).
   PubMed Web of Science ®Google Scholar
• Roviello G , CatalanoM, DeGiorgi Uet al. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. Front. Oncol.12, 918413 (2022).
   PubMedGoogle Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• NIH/NCI . Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Protocol147 (2017). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
   Google Scholar
• Decoster J , GallucciM, IselinA-MR. Best practices for using median splits, artificial categorization, and their continuous alternatives. J. Exp. Psychopathol. JEP2, 197–209 (2011).
   Google Scholar
• Kim J , KimH, HongJYet al. Prognostic factors of survival with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as second-line therapy for patients with metastatic colorectal cancer. J. Cancer12(2), 460–466 (2021).
   PubMed Web of Science ®Google Scholar
• Hamaguchi T , DendaT, KudoTet al. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci.110(11), 3565–3572 (2019).
   PubMed Web of Science ®Google Scholar
• Nozue M , OshiroY, KurataMet al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol. Rep.9(1), 109–112 (2002).
   PubMed Web of Science ®Google Scholar
• Park HS , ChunYJ, KimHSet al. Clinical features and KRAS mutation in colorectal cancer with bone metastasis. Sci. Rep.10(1), 21180 (2020).
   PubMed Web of Science ®Google Scholar
• Tabernero J , Van CutsemE, LakomýRet al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur. J. Cancer50(2), 320–331 (2014).
   PubMed Web of Science ®Google Scholar
• Sandfeld-Paulsen B , Aggerholm-PedersenN, Winther-LarsenA. Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis. Transl. Lung Cancer Res.10(2), 651–661 (2021).
   PubMed Web of Science ®Google Scholar
• Schutz FAB , XieW, DonskovFet al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur. Urol.65(4), 723 (2014).
   PubMed Web of Science ®Google Scholar
• Kim HS , YiSY, JunHJet al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology73(3–4), 192–197 (2007).
   PubMed Web of Science ®Google Scholar
• Djamgoz MBA . Hyponatremia and cancer progression: possible association with sodium-transporting proteins. Bioelectricity2(1), 14 (2020).
   PubMedGoogle Scholar